Video - Results from #120

REVIEW UroToday

mHSPC VL

Search

Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans Details Alicia Morgans presents a lecture on the contemporary management strategies for hormone sensitive prostate cancer with a focus on systemic therapy including chemohormonal approaches and the use of abiraterone for metastatic hormone sensitive disease. In the discussion, Alicia compares and contrasts both the CHAARTED and STAMPEDE data and provides an update on treatment today, including evidence ba...
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans Details Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. Dr. Morgans emphasizes how patients should be included in the conversations and the decisions on treatment selection and considerations on efficacy, safety, and potential toxicities. She reiterates that...
The Role of the Nurse Practitioner in the Treatment of mHSPC - Leanne Schimke Details Leanne Schimke begins her presentation discussing the role of the nurse practitioner in the treatment of patients with advanced prostate cancer. She first looks at newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) patients. Also, presented is treatment options for mHSPC and the administration, adverse effects, nursing considerations, and drug interactions of these treatments. Bi...
Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans Details Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in...
STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen Details (Length of Discussion: 12 min) Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. Silke shares the clinical trial design and data...
A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney Details (Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton Details Robert Hamilton, a Staff Urologic Oncologist from Princess Margaret Cancer Centre in Toronto, Canada discusses radical prostatectomy for patients with oligometastatic prostate cancer. He overviews the clinical and biological rationale for radical prostatectomy in the oligometastases setting and highlights the role of novel imaging. He reviews four major PET tracers receiving a lot of attention: PS...